Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States

利福平 医学 幽门螺杆菌感染 幽门螺杆菌 克拉霉素 内科学 第一行 胃肠病学 肿瘤科
作者
Ismaeel Yunusa,Bryan L. Love
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:118 (4): 635-644 被引量:7
标识
DOI:10.14309/ajg.0000000000002146
摘要

INTRODUCTION: The economic and clinical implications of eradicating Helicobacter pylori ( H. pylori ) with vonoprazan-based and rifabutin-based regimens vs other existing prepackaged first-line treatment options in the United States are unknown. Therefore, we evaluated the cost-effectiveness of vonoprazan-based and rifabutin-based and other prepackaged regimens for the first-line treatment of H. pylori from the perspective of US healthcare payers. METHODS: We used the state-transition Markov model to conduct a cost-effectiveness analysis of H. pylori eradication with clarithromycin triple, bismuth quadruple, vonoprazan dual, vonoprazan triple, and rifabutin triple regimens. In a cycle length of 2 months, the model estimated the expected costs (expressed in 2022 US$), expected quality-adjusted life-years (QALY), incremental cost-effectiveness ratios, and expected net monetary benefit over 20 years. In addition, we accounted for the present value of future costs and QALY by applying a 3% discounting rate. RESULTS: In this study, rifabutin triple therapy had a lower expected cost but was more effective than clarithromycin triple, bismuth quadruple, and vonoprazan dual regimens; hence, it dominated them. Vonoprazan triple therapy had a higher expected cost (US$ 1,172 vs US$ 1,048) and expected QALY (14.262 vs 14.256) than rifabutin triple therapy, yielding an estimated incremental cost-effectiveness ratio of US$ 22,573/QALY. The study suggested that vonoprazan triple treatment had the highest expected net monetary benefit and was the most cost-effective at willingness-to-pay thresholds between US$50,000 and US$150,000 per QALY, followed by rifabutin triple therapy. DISCUSSION: H. pylori infection eradication with vonoprazan triple therapy would provide the greatest net health and monetary benefit from the perspective of US healthcare payers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
u806686发布了新的文献求助10
刚刚
刚刚
xwy发布了新的文献求助10
刚刚
研友_VZG7GZ的应助被叶林海采纳,获得10
刚刚
1秒前
鳗鱼元正发布了新的文献求助10
1秒前
1秒前
李李李发布了新的文献求助20
2秒前
2秒前
molihuakai的应助被爱听歌的青筠采纳,获得10
3秒前
霸气导师完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
u806686发布了新的文献求助10
3秒前
3秒前
wy.he的应助被醉熏的断缘采纳,获得10
4秒前
ding的应助被兮非采纳,获得10
4秒前
4秒前
匆匆发布了新的文献求助10
4秒前
大气的灯泡完成签到 ,获得积分10
4秒前
XX发布了新的文献求助10
5秒前
6秒前
u806686发布了新的文献求助10
6秒前
7秒前
8秒前
8秒前
meng发布了新的文献求助10
8秒前
8秒前
9秒前
PP发布了新的文献求助10
9秒前
orixero的应助被王不留行采纳,获得10
9秒前
9秒前
飘逸尔芙发布了新的文献求助10
10秒前
dudu发布了新的文献求助10
10秒前
Luyz完成签到,获得积分10
11秒前
东少完成签到,获得积分10
12秒前
12秒前
闫诗宇发布了新的文献求助10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193605
求助须知:如何正确求助?哪些是违规求助? 9579751
关于积分的说明 21867369
捐赠科研通 7793242
什么是DOI,文献DOI怎么找? 3437325
关于科研通互助平台的介绍 2560761
邀请新用户注册赠送积分活动 2484193